Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VDRM went from no news on Etrade to 2 articles in a week:
Developments in the Erectile Dysfunction Markets -2-
Aug 28, 2017 09:50:00 (ET)
FinancialBuzz.com News Commentary
NEW YORK, August 28, 2017 /PRNewswire/ --
A research report by Life Science Intelligence (LSI), Erectile dysfunction (ED) is estimated to affect more than 150 million men worldwide and the number of men with ED is expected to double by the year 2030. Although most cases are not reported, it is estimated that more than 30 million men affected in the United States. The report indicates that ED is more common in men older than age 65, most men older than the age of 40 experience occasional difficulty and it is estimated that more than 50% of men older than the age of 40 report periodic episodes of ED. Creative Medical Technology Holdings, Inc. (OTC: CELZ), Easton Pharmaceuticals, Inc. (OTC: EAPH), VIVUS, Inc. (NASDAQ: VVUS), Apricus Biosciences, Inc. (NASDAQ: APRI), ViaDerma, Inc. (OTC: VDRM),
A new report by Visiongain forecasts that the world market for sexual dysfunction drugs will reach $7.7 billion in 2019, or rising further to 2026. The market will be stimulated by ageing populations, rising incidence of cardiovascular and metabolic disorders, new drug delivery technologies, emerging test techniques and the rising female sexual dysfunction drugs submarket. Sandra Wenas, a senior pharmaceutical industry analyst in Visiongain stated, "We believe that there will be positive changes in the way societies perceive male and female sexual dysfunctions. Increased awareness and more self reporting will expand the size of patient populations. Presently there is still divided opinion on whether female sexual dysfunction is a physiological disease that needs medication or whether it is a psychological condition."
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) earlier today announced that, "completion of enrollment in the Company's clinical trial assessing safety and efficacy of its CaverstemTM procedure to treat erectile dysfunction in patients who do not respond to currently available treatments. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
"The CaverstemTM procedure, which uses the patient's own bone marrow derived stem cells to induce arterial and venous regeneration, is an outpatient procedure able to be conducted by Urologists in their medical facilities. We are using a patient's own cells and we do not manipulate the stem cells through the use of chemicals, growth factors or expansion and have experienced no procedure-related safety issues," said Dr. Thomas Ichim Co-Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.
The clinical trial covering patients ages 18 to 80 received Institutional Review Board (IRB) approval in December 2016. The trial is sponsored by us based on our patented technology and is conducted by Dr. Jacob Rajfer, Principal Investigator and Los Angeles Biomedical Institute at Harbor - UCLA Hospital in Torrance, CA.
"I am pleased with the expedience and efficiency at which enrollment was reached. As someone who regularly sees patients suffering from treatment non-responsive erectile dysfunction, I am excited to see the development of a novel approach to treating this condition using the patient's own natural regenerative processes," said Dr. Alexander Gershman, member of the Company's Scientific Advisory Board and Director of Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center."
"We are very fortunate to work with the expert team at Los Angeles Biomedical Institute - UCLA/Harbor Hospital who have done an outstanding job with subject recruitment, screening, treatment and follow-up. We firmly believe that we are on schedule for commercialization of the Caverstem TM procedure through publication and presentation of trial results, marketing, licensing, training and sales in 2018," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.
Easton Pharmaceuticals, Inc. (OTC: EAPH) s is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. According to the company's Product and Market Overview, "When it comes to treating pain, sexual dysfunction and other disease states that emanate from structures of the body below the skin, topical therapy is not effective unless the therapeutic agent can cross the outer layer of the skin (stratum corneum) which acts as a protective barrier. This layer consists of numerous dead cells and cells in transition, which collectively forms an effective barrier to penetration of substances, such as bacteria, in the air or in water. Thus the stratum comeum plays an important role in protecting the body from invasion by harmful substances."
VIVUS, Inc. (NASDAQ: VVUS) is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. STENDRA or avanafil is approved in the U.S. by the FDA for the treatment of erectile dysfunction. VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries. On August 3(rd) , the company reported financial results for the quarter ended June 30, 2017.
Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has a product called Vitaros, a candidate in the United States for the treatment of erectile dysfunction. Vitaros is a topically-applied cream formulation of alprostadil, which dilates blood vessels, combined with a proprietary permeation enhancer NexACT, which directly increases blood flow to the penis, causing an erection. Vitaros is currently in development in the U.S. and approved and commercialized in certain countries outside of the U.S. Allergan owns the rights to Vitaros in the U.S. and in September 2015, the company entered into an agreement with Allergan to license the U.S. development and commercialization rights for Vitaros.
ViaDerma, Inc. (OTC: VDRM) is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. The company's lead product candidate, Vitastem, broad spectrum tetracycline-based topical antibiotic with proven results. Vitastem could be used in a variety of potential markets, including erectile dysfunction, burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, and pain management.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated three thousand dollars for financial news dissemination and pr services by a non-affiliate third party for creative medical technology holdings, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or
continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .
For further information:
Media Contact: info@financialbuzz.com , +1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
(END) Dow Jones Newswires
August 28, 2017 09:50 ET (13:50 GMT)
I-Hub Members get 50% off of MJAC tickets!! Somebody should tell Otiko!!
Investors Hub mjac2017@investorshub.com via listserv.advfn.com
11:26 AM (3 hours ago)
to me
Dear iHub Member,
As a member of Investors Hub we would like to offer you 50% off for MJAC 2017 tickets.
Please use the following code on www.mjac2017.com for the 50% discount - FLASH50
Or call me on 714 978 4581 and I will arrange personally for you.
Many thanks
Matt
Ahhhh, hopefully your purchase is big enough to help the PPS.
A rising tide lifts all boats so to speak!!!
Good luck good sir!!! Jim
Let's hope so!!! I am starting to crack over here!!!!
What makes you think tomorrow is going to be great?
Thanks, Jim
Hey IR: I heard Los Angeles is in the same state as your offices.
Why are you not registered at the MJAC Cannabis Conference that starts this Friday September 1st in Los Angeles? (You could Uber to it!!!)
Asking for a friend....
"they said update very soon"...... March 2015, May 2016, March 2017, May 2017, August 2017, September.... At this point I am basically trying to shame them into doing any form of a direct release to stock holders.
I believe the stock ran up on the Galaxy news, and is dropping based on the fact September may see dilution, so everyone is in Fear Of Missing Out mode and one day we are up, next we are down. And for good reason!
It is not charts, or consolidation, it is literally a little news here, no news there, September is around the corner, and we bounce accordingly.
Not trying to be negative, but I am starting to hold IR and their "You just wait and see, we'll share soon, and it will be great" cryptic messages to the fire a bit.
How about some real news on if/when dilution is going to occur and the expected effect on PPS?
I am long on this but let's be honest: Whether the man speaks at a mega convention or the stock is going to be diluted (as was promised not to happen... until September!), we are told nothing directly. All of the news supposedly comes from other organizations that have heard something and are reporting on it (PR Newswire, etc).
As investors, we should have a news release direct from VDRM occasionally. And before someone tells me to contact IR, I have, on numerous occasions, where I got promises that news is just around the corner. When I asked IR about Galaxy, they wanted to check to make sure their material was accurate and they will get back to me. You didn't have confirmed info BEFORE the deal was made?!?!
I know, this will probably get pulled, but let's be honest, at some point, we are due some direct info BEFORE PR Newswire gets it. And have it be a direct statement, no a news articles with a couple quotes.
Thanks, Jim
"paint down by eod" is when someone sweeps in at the last second and drops the stock price so as to make the price drop right at the end of the day when no one has time to bring it back up so then the news cycle is that it closed down.
EOD stands for "End of Day".
Shorters and others fighting this stock can turn a good day bad at the last minute, so while it was a good day, it got a paint job over it that makes it look bad.
Take care, Jim
Hi tganz,
About VDRM? On their news tab within the Quote Details widget?
I read about a lot of my stocks through this widget, but this is first VDRM news that has shown up for me.
Where are you seeing other VDRM news on Etrade if not in the Quote Details widget? I will add whatever feature you are seeing it in.
Thanks, Jim
Thanks for mentioning Scottrade Jayay222!! I had wondered if it was an Etrade only issue.
Glad to know other trading platforms were treating VDRM the same way and that it wasn't Etrade being behind other trade sites.
Take care, Jim
VDRM FINALLY Gets An Article On Etrade!!!! If you use Etrade and have ever clicked the NEWS tab in the "Quote Details" widget while viewing VDRM, you probably noticed it has always said "No News Available For This Ticker". Etrade archives news articles for the tickers they cover, so they had literally never covered a news article about VDRM before. Well, that is no more!!!
While I am sure this has appeared elsewhere, I had not seen it yet, but more importantly, Etrade has never carried news for VDRM. Etrade picked it up from Dow Jones Newswire per the sign off at the end, which got it from PR Newswire and Marketnewsupdates.com.
I have pasted the article, which has two mentions of VDRM, below:
Cannabis CBD Product Revenues Continued Growth Projected to be Billion Dollar Industry
Aug 24, 2017 08:45:00 (ET)
MarketNewsUpdates.com News Commentary
PALM BEACH, Florida, August 24, 2017 /PRNewswire/ --
In an article published on Forbes this week, Hemp-derived cannabidiol (CBD) is projected to be a billion-dollar market in just three years, according to a new report by Brightfield Group. The data company estimates that hemp CBD sales have already hit $170 million in 2016 and a 55% compound annual growth rate over the next five years will cause the market to crack the billion-dollar mark. Brightfield determined that 64.5% of the sales come through the online channel followed by 17.8% at smoke shops. Dispensaries were third, with 9% of the sales and health stores and doctor's offices rounded out the top five. This high growth market is expected to get even stronger for companies such as: PotNetwork Holding Inc. (OTC: POTN), Hemp Inc. (OTC: HEMP), Agritek Holdings Inc. (OTC: AGTK), ViaDerma Inc. (OTC: VDRM), Leafbuyer Technologies, Inc. (OTC: LBUY).
PotNetwork Holding Inc. (OTC: POTN) - Record Breaking Months Again Surpassed, With July Revenues Nearing 1.5 Million Dollars - POTN is delighted to announce that its wholly-owned subsidiary, Diamond CBD, Inc., has delivered yet another considerable increase in revenues month over month. For the month of July 2017, it achieved record breaking revenues of $1,459,137, which exceeded its June 2017 results by more than 30% . Read this and more news for POTN at: http://www.marketnewsupdates.com/news/potn.html
"We are very pleased with how the numbers have continued to gain over the summer. We are consistently setting new sales records month after month and are excited to be able to report this type of continuing growth. We have taken our marketing efforts seriously. A commitment that is surely being revealed in the ongoing sales numbers," stated Maria Gomez, Regional Vice President of Sales for Diamond CBD, Inc.
The Company recently reported that, based on earlier filed financial statements with OTC Markets, PotNetwork Holding, Inc. is on track to exceed its projections set forth for 2017. With reported revenues of $5,077,625 for the first 6 months of fiscal 2017, and a net profit of $369,237, the Company concluded the first half of 2017 with a positive net cash flow of $395,009.
In other industry developments and market performances of note:
Hemp Inc. (OTC: HEMP) closed up over 8% on Wednesday with over 23.5 million shares traded on the day. The company recently announced its NuAxon Tech CO2 Supercritical Extractor has officially launched and is in its first phase of operation. The company previously purchased the NuAxon Tech Industrial CO2 Supercritical Extractor from NuAxon BioScience, manufacturer and the producer of the world class, large capacity CO2 Supercritical Extraction equipment as part of a joint venture with Freedom Leaf, Inc. (OTCQB : FRLF), NuAxon's global exclusive distributor for the cannabis/hemp industry. After thorough testing and debugging, corporate executives are now commencing their "hemp oil extraction infrastructure," one of the company's current four underlying industrial hemp infrastructure components.
Agritek Holdings Inc. (OTCQB: AGTK) closed up 3.72% with over 12.3 million shares traded on the day. The company recently announced the Company's first orders from its' state licensed manufacturer for its brand "MicroDose" Oral Strips or "MD Strips" for the medicinal market of California. First orders and samples are being sent to dispensaries and local delivery services in both San Diego and Orange County this month. Agritek Holdings will provide the licensing and packaging to produce the exclusive line of 10mg and 50 mg oral strips as a medicinal alternative for patients. The Agritek "Microdose" brand will be produced and expected to be distributed through its permitted manufacturer and collective to 140 plus dispensaries throughout California over the coming months. AGTK will receive a flat fee per single package designed exclusively by Agritek Holdings with the first 10,000 units being delivered by the end of the month.
ViaDerma Inc. (OTC: VDRM) closed up over 4% on Wednesday with over 12.3 million shares traded by the market close. The company recently announced that it has appointed Galaxy Solutions, Inc. as its sales representative for its first aid topical antibiotic which will be sold under the brand name Vitastem in select markets of Asia Pacific, starting in Japan. The agreement includes sales and marketing responsibilities of the Vitastem brand and possible other brands that will be developed for specific market segments. Galaxy Solutions, Inc. will work to sell directly to larger customers and to distributors and will be the primary provider of service and support in the covered markets. "With Galaxy Solutions as our sales representative, we will immediately have access to the professional segment of our target markets," said Dr. Chris Otiko, CEO of Viaderma, Inc.
Leafbuyer Technologies, Inc. (OTC: LBUY) closed up over 13% on Wednesday at $2.65. Leafbuyer Technologies, a leading cannabis technology platform, announced this week that it has renewed its partnership with the Cannabist, a marijuana news website from the award-winning Denver Post, and will continue as its official deals partner. Kurt Rossner, CEO and Co-founder of Leafbuyer, commented, "We are very pleased to renew this significant partnership. Being the official deals platform for the Cannabist has expanded our reach to consumers all over the country. Millions of cannabis consumers each month read the Cannabist for their great industry news. We believe having the right partnerships with established industry heavyweights will help expand Leafbuyer's brand nationally. We expect 2018 will be a watershed year in this industry and we are excited to grow with the Cannabist."
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty-nine hundred dollars for news coverage of the current press release issued by PotNetwork Holding Inc by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information:
E-mail:info@marketnewsupdates.com
+1(561)325-8757
SOURCE MarketNewsUpdates.com
(END) Dow Jones Newswire
Fantastic!! This is the first chance I have had to log on today.
Can you share a link to where you got that info.
That is huge and should be stickied!
Thanks hghscurry! Jim
Thanks for the reply and your candor.
Here is how I see it:
People usually first come across a stock due to good press and good perception. But some of our MMJ companies just can't catch that break:
VDRM has made it, so far anyway, through being part of a lawsuit, without having to cave so far and it looks like they might prevail. They have also done well with poor PR work when at times they could have been heralded more.
So, VDRM will continue to make it in part because it is defying perception and people can see that.
CNBX has great things going for it but low perception level. People are not paying attention to it because it isn't generating buzz. In reality, it may be part of curing cancer, so in the long run, CNBX is going to do well.
OWCP was supposedly the best company of them all and I was advised to get in at $ 1.60. I did buy a small holding of shares and have held them. OWCP does not have perception defying skills going for it right now OR a lot of quiet activity brewing like CNBX does. So, while at one time OWCP was seen as a leader, I see it as low on the list compared to VDRM and CNBX.
Just my opinion but watching this everyday for over 2 years, it seems to be some things are going better than we are getting to hear about, and one that everyone got to hear about and thought was going to do great (OWCP), may be a first class ticket on the Titanic. Just a thought.
Take care, Jim
Is that because we have landed where we were expected to reach or some other reason?
Thanks, Jim
Ruse? Dropped around .018 for a few minutes and now coming back up. Are you saying they did the Biogenx and Galaxy press releases?
Because IR has replied regarding the fact the companies use slightly different names when they apply their own brand (Vitastem, Viabaclene, etc). So IR is confirming the distribution deals, Biogenx being negotiated clear back around March and Galaxy here in August.
What ruse are you referring to?
Thank you, Jim
Can anyone answer when/why did Viabaclene become Vitastem? Is this in Japan/Asia only, due to the court case, a re-branding, or a different product than the Viabaclene we have been discussing?
Have sent this question to IR but I sometimes get answers here quicker. Thanks, Jim
"has appointed Galaxy Solutions, Inc. as its sales representative for its first aid topical antibiotic which will be sold under the brand name Vitastem in select markets of Asia Pacific, starting in Japan".
Email I received from IR regarding Galaxy when I requested info:
"ViaDerma Investor Relations <info@viadermalicensing.com>
7:10 PM (7 hours ago)
to me
Sure thing. Let me verify the info I have is accurate and I will send it to you.
Thanks
---
ViaDerma Investor Relations
310-734-6111
My email to IR:
Hi IR,
Can you provide us some background or links to Galaxy Solutions, Inc. ? A quick Google search didn't seem to find them.
Loving the news today, but can usually find information on the companies my investments partner with. Not having that luck with Galaxy. Please provide anything that you can (other companies that have utilized them, links to stories they are featured in, etc).
Thank you, Jim
Volume just broke 33 million for the day and gonna blow past 34 million while the ten day average is 5 million!! YES!!!
492,000 shares were available for .02 and they are getting gobbled up! Somebody is moving hard on these higher prices!!!
Average 10 day volume around 5 million. Today's volume: Over 32 million!!
FANTASTIC!!!!!!!!!!!!!
God I hope so!!! Not wanting to be negative, and considered not posting anything and just letting it ride, but decided I needed to know whether to sell before the BS Meter went off for someone else or to hold and enjoy the reality we are all hoping for.
A dime does me great. .50 does me even better, and so on. Love that we are seeing positive news and doubled our price this week, but not wanting to just blindly sit through another BS session.
Thanks for reaching out and let's hope this is for real!!!
I agree, neither link is associated, but was all I could find.
I emailed IR and asked for info on other companies Galaxy has worked with, articles they are listed in, etc.
I love the price reversal and want this to be real as much as anybody, but still want the DD.
Thanks, Jim
I did. I have posted my email below. In the meantime, I thought I would ask among our group if anyone has DD on them.
Thanks, Jim
Hi IR,
Can you provide us some background or links to Galaxy Solutions, Inc. ? A quick Google search didn't seem to find them.
Loving the news today, but can usually find information on the companies my investments partner with. Not having that luck with Galaxy.
Please provide anything that you can (other companies that have utilized them, links to stories they are featured in, etc).
Thank you, Jim
Loving how you are thinking whatarush12!!! This stock deserves a good run!!!
Very happy with the price reversal today, but does anyone have DD on Galaxy Solutions, Inc. that is listed as handling the distribution out of Japan?
The two links I was able to find regarding Donald Heath or a Galaxy Solutions in Japan (came up GalaxeSolutions, an IT company) are below.
Please advise if there is other DD available.
Thank You, Jim
https://www.internetsociety.org/history-timeline/donald-heath-named-president-and-ceo-internet-society
http://www.galaxe.com/Gx-About-Us.aspx
Your comment is a trend that I see across a lot of stocks.
Being on Eastern Standard Time (EST), I call them the 1 o'clockers.
It seems the market always gets more volatile around 1pm EST. I believe it is due to those who get a chance to check and change their portfolio over lunch.
I traded Lions Gate for around 5 years (LGF.A) and it was the same with that stock as with pretty much every other stock I have traded.
Take care, Jim
Most of what we are seeing in the PPS drop is the fact that the case is dragging on and nothing positive is happening during that due to the company, et al do not want to release anything that would influence Keough to keep fighting, etc.
During this time, people that have chosen not to stick with VDRM are selling, so the price is dropping heavily with nothing positive to hold it up.
Many of us hold a quarter million shares or more, so when someone with a million plus decides to liquidate on a day that 3.5 million is the total volume sold, you are going to see big drops.
Nothing has really changed with the company, the product, etc, just a mass exodus with nothing positive to bolster the drop in price.
When that evens out, the drops will even out. And if the case gets resolved and PR's can start flowing again, there is a good chance of a quick upswing in PPS.
The toughest thing is the wait and watching the drops during the exodus.
Take care, Jim
This reply is written better than any of the press releases the various "PRNEWS" type sites post.
I take wording and spelling into account. When a supposed "press release" cannot get those things right, I question the merit of the release.
While I will be the first to admit that I have started to question what the future holds for those of us that hold VDRM shares, seeing something this well worded gives me hope.
That may make me laughable, but as bad as press releases have been from various companies over the past couple years, professionalism gives me hope!!
Take care, Jim
A good reason to let the price slump: I have been involved with companies that are looking down the barrel of a pending settlement. If the court case comes to a settlement (ie, Viaderma et al have to give some money to Keough to end the case), the less the company is worth, the less you have to pay.
If they settle for a percentage of the company's value in cash instead of shares, then you have to hand over less cash if the company is worth less.
One example is a trust I was involved with where the widow took against the trust after taking what she was given in the company founder's will.
She was able to take against the trust due to an antiquated law that made it so wives would not be dealt out of their fortunes by being given their house but no piece of the company.
We got a call one evening during negotiations and the lawyers said a tentative deal had been reached. The wife would get 1/3 of the company as the law stated, in cash, but they dropped the value of the company from around 1 million to 200,000. So, the son only had to write a check for around $ 70,000 to his step mom, instead of $ 333,333.
This may be why Otiko et al are allowing the company to whither on the vine, not releasing new PR's and not shipping, so as to not have VDRM be that much more of a gem to fight for and pay for.
Just a thought as we see VDRM winning in court but not promoting itself.
A volume of 6,768,212 and it closed Green! WOW on that volume!!!!
The Rohrabacher-Farr amendment keeps things where they were pre-Sessions, so his flexing his muscles is for political show to try to win political support and create news other than Russia and whether he will be fired.
But the US is quickly becoming a minor player in MMJ when it comes to R&D. If a non-US corporation or arm of a corporation decides they want to own the progress CNBX has made, one country dragging its feet will not be reason enough to pass up the opportunity.
Sessions has been turned down at every turn, including personally by Congress when he sent a letter asking for the power to go against MMJ. Part of which was covered in the previous post below.
Congress firmly told Sessions that not only would they not fund interference with MMJ, but told Sessions that, if they find he is using other means to go after MMJ, they will de-fund whatever means he uses. In effect, they were pretty firm with someone desperate to find a win.
"The Senate Appropriations Committee Renewed the Rohrabacher-Farr amendment, which prohibits the Justice Department from spending funds to interfere with the implementation of state medical cannabis laws.
The House released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice.
In plain English, US Attorney Jeff Sessions can talk all he wants, but he has no "teeth" to go after legalized States".
DD Regarding CNBX being held down: This is the what I posted back in May regarding CNBX price being torpedoed by a number of articles that obviously all started by the same person and then were disseminated on different sites under different author names.
The post below includes an email from the OTC Board where CNBX is traded.
Fear not, CNBX will come raging back!!! But we have to get through people like this working to control its price:
jim992
Wednesday, 05/17/17 02:24:21 AM
Re: sinky post# 1558
Post # of 2231
Alan Brochstein wrote the BS article "Cannabics Pharmaceuticals Triggers Regulatory Scrutiny After Parabolic Spike" that caused CNBX to fall from $ 7+.
When I contacted the OTC board about his claims of "scrutiny" and provided them his article, they replied with the following denouncement that there had been no "scrutiny" of CNBX and stated that they believed Brochstein's article was a statement from CNBX, which it obviously was not.
Here is their reply regarding his article and their views of Brochstein speaking with any knowledge. Keep in mind the article title above regarding "Regulatory Scrutiny":
"Thank you for your email. Please note that OTC Markets has never announced a review of any nature regarding the company; and for further clarification, OTC Markets Group is not a regulatory agency. The links you included reference the company’s press release disseminated on February 23, 2017.
Please let us know if you have any additional questions.
Sincerely,
Gareth Colglazier
OTC Markets Group
100 M Street SE, Suite 220 / Washington, DC 20003
Office: (212) 896-4458
Email: gareth@otcmarkets.com"
So Brochstein claimed "regulatory scrutiny" of CNBX where there was none, and when I included his article in my email to OTC, (full article linked below), they thought it was from CNBX. Anyone that read the article would know CNBX did not put this out.
In short, Brochstein has already proven in the last 90 days to be a person that likes to claim knowledge he does not have, claim "regulatory scrutiny" where there has been none, and when his articles are provided to the OTC Board, they denounce him as probably a nut working to stir up CNBX or MM news and nothing more.
He has cost us enough. Do not give someone that OTC has gone on record as not having the knowledge he claims to have any more credence than he has already falsely given himself.
Jim
https://www.newcannabisventures.com/cannabics-pharmaceuticals-triggers-regulatory-scrutiny-after-parabolic-spike/
This is discussed everyday at VDRM. A lot of people wanting to buy, no one wanting to sell.
But you make a good point: Day after day, with the average volume over the last 10 days at around 500,000 at some point this thing should be going higher.
At what point do all of the positives CNBX has experienced this year turn into bigger dollars?
Too much is happening for it to simply be 1 or 2 years out without people like Alan Brochstein manipulating the price with his fear mongering articles that claim OTC is doing things that the head of OTC has said they are not even capable of doing.
To promote himself and the stocks he is pushing, Brochstein torpedoed CNBX back in February when it shot to over $ 7 with that BS article about CNBX bringing OTC "scrutiny". OTC did not do so and has no authority to do so per the head of OTC, which stated that article was pure PR. PR for himself and his funds.
The Rohrabacher-Farr amendment keeps things where they were pre-Sessions, so his flexing his muscles is for political show to try to win political support and create news other than Russia and whether he will be fired.
But the US is quickly becoming a minor player in MMJ when it comes to R&D. If a non-US corporation or arm of a corporation decides they want to own the progress CNBX has made, one country dragging its feet will not be reason enough to pass up the opportunity.
Sessions has been turned down at every turn, including personally by Congress when he sent a letter asking for the power to go against MMJ. Part of which was covered in the previous post below.
Congress firmly told Sessions that not only would they not fund interference with MMJ, but told Sessions that, if they find he is using other means to go after MMJ, they will de-fund whatever means he uses. In effect, they were pretty firm with someone desperate to find a win.
"The Senate Appropriations Committee Renewed the Rohrabacher-Farr amendment, which prohibits the Justice Department from spending funds to interfere with the implementation of state medical cannabis laws.
The House released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice.
In plain English, US Attorney Jeff Sessions can talk all he wants, but he has no "teeth" to go after legalized States".
Possible Buyout PPS Price Structure: If a buyout takes place, the purchaser will probably purchase Cannabics with stock of their own company, and probably do something along the lines of giving 1 share of their stock for every 2 shares of CNBX.
Merck (MRK), for example, closed today at a little over $ 63 a share. So dividing that in half with the 2 shares of CNBX for each 1 share of MRK would make CNBX worth a little over $ 30 a share had the buyout happened today with MRK as the buyer.
We can guess who the buyer will be, but based on what that company is worth and what the stock trade structure is will determine what we are worth when bought out.
CNBX Buyout: Sooner Rather Than Later? As I see the news of CNBX advancements coming along more rapidly than ever, it leads one to wonder: At what point will someone take a shot at a takeover/buyout before the company PPS takes off again and it is that much more expensive to buy?
With all of the talk of the price of this stock and others being held down, at some point, it is common sense that a big pharma or other mega corporation will move on owning Cannabics instead of fighting it, competing against it, or watching from the sidelines as it takes off under someone else's name.
If it hadn't had such a run 6 months ago, followed by a slew of recent advancements, it would be understandable if CNBX fell by the wayside like some other MMJ companies. But Cannabics has really had a banner 2017. Who will own it, and when, will soon become more solid conversation points than what the PPS will go to.
I'd be interested to know if anyone else is starting to feel like major news might actually come before another major PPS move.
Take care, Jim
On one chart I am seeing today's high as $ 1.58. On another I am seeing $ 1.41. ??? Both charts being accessed via Etrade.
Open 1.40
Previous Close 1.40
Day Hi 1.58
Day Lo 1.22
52 Week Hi 7.60(2/22/17)
52 Week Lo 0.035(8/11/16)
Open 1.40
Previous Close 1.40
Day Hi 1.41
Day Lo 1.22
52 Week Hi 7.60(2/22/17)
52 Week Lo 0.035(8/11/16)
Rohrabacher-Blumenauer amendment re-authorized today!!
Initially enacted by Congress in 2014, the amendment maintains that federal funds cannot be used to prevent states from “implementing their own state laws that authorize the use, distribution, possession or cultivation of medical marijuana.”
So Sessions cannot go after MMJ as he has been falsely claiming!!!
Rebuking Sessions & denying him funds all in 1 day!!
Senate Appropriations Committee voted July 27th to "Continue To Protect Lawful Medical Marijuana Programs" and deny money to any federal agency trying to do otherwise! They are also voicing opposition of Sessions and any acts he is considering on MMJ!!
Link Below:
Senate Update: The Senate Appropriations Committee is passed the Rohrabacher-Blumenauer amendment on Thursday, July 27th by a voice vote.
http://act.norml.org/p/dia/action4/common/public/?action_KEY=20976
Closed $1.50 but BID is $1.53, ASK $1.54. Heading the right way to start Wednesday.